Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD1c+ and CD141+ myeloid dendritic cells
- Development stage
- Unknown
- Lead developer
- Universitair Ziekenhuis Brussel
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intratumoral
01
Overview
CD1c+ and CD141+ myeloid dendritic cells is an autologous cell-based immunotherapy developed by Universitair Ziekenhuis Brussel. The therapy consists of two specific subsets of myeloid dendritic cells (myDCs)—CD1c (BDCA-1)+ and CD141 (BDCA-3)+—which are isolated from a patient's peripheral blood via leukapheresis. These cells are administered via intratumoral injection, where they function as professional antigen-presenting cells to prime and activate tumor-specific T-cell responses. By enhancing the recruitment and activation of effector T cells within the tumor microenvironment, the therapy aims to overcome resistance to immune checkpoint inhibitors. It is currently being evaluated in the Phase II LUSCID trial (NCT04571632) in combination with stereotactic body radiation therapy (SBRT), systemic pembrolizumab, and intratumoral avelumab and ipilimumab for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC).
- Other names
- CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDCautologous myeloid dendritic cellsmyDC
Beyond the preview
Go deeper on CD1c+ and CD141+ myeloid dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD1c+ and CD141+ myeloid dendritic cells.